After months of anticipation, US Food and Drug administration has finally granted traditional approval to lecemab, a drug that's been shown to significantly slow the progression of Alzheimer's.
By Natalie Grover LONDON (Reuters) - Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability .
Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.
European Alzheimer's experts unconvinced by new Eisai, Biogen drug – The Frontier Post thefrontierpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thefrontierpost.com Daily Mail and Mail on Sunday newspapers.
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer's disease (AD)